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A B S T R A C T
The innate immune system is implicated in Parkinson’s disease (PD), but peripheral in-vivo clinical evidence of
the components and driving mechanisms involved and their relationship with clinical heterogeneity and pro-
gression to dementia remain poorly explored.
We examined changes in peripheral innate immune-related markers in PD cases (n = 41) stratified according
to risk of developing early dementia. ‘Higher Risk’(HR) (n = 23) and ‘Lower Risk’ (LR) (n = 18) groups were
defined according to neuropsychological predictors and MAPT H1/H2 genotype, and compared to age, gender
and genotype-matched controls. Monocyte subsets and expression of key surface markers were measured using
flow cytometry. Serum markers including alpha-synuclein, inflammasome-related caspase-1 and bacterial
translocation-related endotoxin were measured using quantitative immuno-based assays. Specific markers were
further investigated using monocyte assays and validated in plasma samples from a larger incident PD cohort
(n = 95).
We found that classical monocyte frequency was elevated in PD cases compared to controls, driven pre-
dominantly by the HR group, in whom Toll-Like Receptor (TLR)4+ monocytes and monocyte Triggering
Receptor Expressed on Myeloid cells-2 (TREM2) expression were also increased. Monocyte Human Leukocyte
Antigen (HLA)-DR expression correlated with clinical variables, with lower levels associated with worse cog-
nitive/motor performance. Notably, monocyte changes were accompanied by elevated serum bacterial en-
dotoxin, again predominantly in the HR group.
Serum alpha-synuclein and inflammasome-related caspase-1 were decreased in PD cases compared to controls
regardless of group, with decreased monocyte alpha-synuclein secretion in HR cases. Further, alpha-synuclein
and caspase-1 correlated positively in serum and monocyte lysates, and in plasma from the larger cohort, though
no associations were seen with baseline or 36-month longitudinal clinical data.
Principal Components Analysis of all monocyte and significant serum markers indicated 3 major components.
Component 1 (alpha-synuclein, caspase-1, TLR2+ monocytes) differentiated PD cases and controls in both
groups, while Component 2 (endotoxin, monocyte TREM2, alpha-synuclein) did so predominantly in the HR
group. Component 3 (classical monocytes, alpha-synuclein) also differentiated cases and controls overall in both
groups.
These findings demonstrate that systemic innate immune changes are present in PD and are greatest in those
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at higher risk of rapid progression to dementia. Markers associated with PD per-se (alpha-synuclein, caspase-1),
differ from those related to cognitive progression and clinical heterogeneity (endotoxin, TREM2, TLR4, classical
monocytes, HLA-DR), with mechanistic and therapeutic implications. Alpha-synuclein and caspase-1 are asso-
ciated, suggesting inflammasome involvement common to all PD, while bacterial translocation associated
changes may contribute towards progression to Parkinson’s dementia. Additionally, HLA-DR-associated varia-
tions in antigen presentation/clearance may modulate existing clinical disease.
1. Introduction
Parkinson’s disease (PD) is clinically and pathologically hetero-
geneous (Rajput et al., 2009; Kehagia et al., 2010; Greenland et al.,
2019). Clinical and genetic factors at diagnosis are known to predict the
rate of progression to dementia, which affects around 50% of patients
by 10 years (Williams-Gray et al., 2013). However, the biological dri-
vers of heterogeneity in progression rates are not fully understood, and
are likely to be complex, arising from interactions between genetic and
environmental risk factors acting at multiple levels.
Mounting evidence from several fields has implicated involvement
of the immune system in PD, however the precise components and
mechanisms involved and their relationships with clinical hetero-
geneity and progression to dementia remain poorly understood. Genetic
studies have indicated associations between immune related gene var-
iants and PD risk (e.g. Human Leukocyte Antigen-DR (HLA-DR),
Triggering Receptor Expressed on Myeloid cells-2 (TREM2), Toll-like
receptor 4 (TLR4) (Nalls et al., 2011; Hamza et al., 2010; Rayaprolu
et al., 2013; Zhao et al., 2015)), while established PD related genes such
as Leucine Rich Repeat Kinase 2 (LRRK2) have demonstrated involve-
ment in the innate immune system (Lee et al., 2017a) and immune-
mediated conditions such as inflammatory bowel disease (Dzamko,
2017). Epidemiological studies have suggested a decreased risk of PD
with anti-inflammatory and immunosuppressant drug use (Gao et al.,
2011b; Ju et al., 2019; Racette et al., 2018) and increased risk with
immune-related conditions such as autoimmune diseases (Chang et al.,
2018) and infections (Pakpoor et al., 2017; Vlajinac et al., 2013). An-
imal models have also suggested involvement of the immune system in
driving PD pathology, with systemic lipopolysaccharide (LPS) admin-
istration (Gao et al., 2011a) worsening alpha-synuclein pathology. Mice
lacking mature T and B lymphocytes (Brochard et al., 2009) have de-
creased cell loss in a toxin-based model of PD and Central Nervous
System (CNS) infiltration of C–C motif Chemokine Receptor2+
(CCR2+) monocytes (Harms et al., 2017) has also been shown to in-
fluence disease pathology and expression.
In the human PD brain, microglial activation has been demon-
strated, both at post mortem (McGeer and McGeer, 2008) and in-vivo
using Positron Emission Tomography (PET) neuroimaging (Gerhard
et al., 2006). Several studies have also identified peripheral immune
changes in PD patients, including increases in serum and secreted cy-
tokines (e.g. Tumour Necrosis Factor (TNF)-α, Interleukin (IL)-1β, IL-2
and IL-10) (Williams-Gray et al., 2016; Qin et al., 2016; Sulzer et al.,
2017), and associations between a more ‘pro-inflammatory’ cytokine
profile at diagnosis and faster motor progression and impaired cogni-
tion over 3 years follow-up (Williams-Gray et al., 2016).
Many immune components are likely to play a role, and studies have
demonstrated changes in adaptive immune factors such as variations in
T lymphocyte subtypes and function (Baba et al., 2005; Cen et al., 2017;
Sulzer et al., 2017; Williams-Gray et al., 2018), decreased B lympho-
cytes (Stevens et al., 2012) and alterations in serum antibody levels
(Scott et al., 2018) in PD. However, many of the key genetic links (HLA-
DR, TREM2, TLR4) and imaging evidence have implicated specific in-
volvement of the ‘innate’ immune system. In addition to central mi-
croglial activation, innate immune abnormalities have been seen in the
cerebrospinal fluid (Schröder et al., 2018) and the periphery, with
changes in monocyte subtype and marker expression (Grozdanov et al.,
2014; Funk et al., 2013). Studies have specifically found increased
numbers of classical monocytes, increased monocyte CCR2, TLR2 and
TLR4 expression (Funk et al., 2013; Drouin-Ouellet et al., 2015), en-
hanced phagocytosis (Grozdanov et al., 2014; Gardai et al., 2013;
Wijeyekoon et al., 2018) and reduced viability in culture (Nissen et al.,
2019).
There is also increasing evidence that alpha-synuclein, the key pa-
thological protein in PD, can be influenced by, and exert influence on,
innate immune pathways and related microbial factors. Microbial in-
volvement has been shown to influence disease pathology (Sampson
et al., 2016) and alpha-synuclein itself may be produced, altered or
trafficked in response to microbial/immune related challenges in-
cluding bacterial endotoxin (Forsyth et al., 2011; Stolzenberg et al.,
2017; Wang et al., 2016). Caspase-1, a key component of the innate
immune inflammasome pathway (which is activated by a range of da-
mage and pathogen associated molecular patterns (DAMPs/PAMPs)),
can cleave alpha-synuclein and make it more aggregable, while Lewy
bodies have been found to stain for caspase-1 together with alpha-sy-
nuclein (Wang et al., 2016). Forms of alpha-synuclein are also capable
of activating the TLR and inflammasome pathways, leading to further
cytokine production and inflammation (Codolo et al., 2013; Gustot
et al., 2015; Kim et al., 2013; White et al., 2018; Grozdanov et al.,
2019).
Although these lines of evidence implicate the innate immune
system in PD, there has been limited characterisation of systemic innate
immune and associated factors and their relevance to clinical hetero-
geneity and disease progression rate, in clinical PD cases. Consequently,
we sought to pursue such an investigation, by characterising relevant
peripheral innate immune components in the blood of a cohort of early-
moderate stage PD cases stratified around risk for early dementia and
paired matched controls without neurological disease. We also in-
vestigated blood samples for the presence of factors implicated in
driving the innate immune changes in PD, including alpha-synuclein
and bacterial endotoxin. We used a data driven approach to explore the
relationships between these factors and innate immune changes and
assessed links with disease status and dementia risk.
2. Materials and methods
2.1. Participants
Ethical approval was obtained from the Cambridgeshire Research
Ethics Committee and written consent was obtained from participants
in compliance with the Declaration of Helsinki. Parkinson’s cases were
recruited from the PD Research Clinic at the John van Geest Centre for
Brain Repair, University of Cambridge.
Inclusion criteria comprised satisfying UK Brain Bank Criteria for
Parkinson’s disease, age 55–80 and Hoehn and Yahr (HY) stage ≤2.
In order to classify patients a priori according to their risk of pro-
gression to dementia, the study utilised factors previously identified
from the CamPaIGN longitudinal cohort study (semantic fluency
score < 20, impaired pentagon copying and H1/H1 Microtubule
Associated Protein Tau (MAPT) haplotype) (Williams-Gray et al.,
2009,2013). Each factor contributes significantly to increased dementia
risk at 10 years, with a hazard ratio of 3.05 for semantic fluency< 20,
2.55 for impaired pentagon copying and 3.08 for MAPT H1/H1
(Williams-Gray et al., 2013).
The ‘Higher Dementia Risk’ (HR) group had at least one of these
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factors at diagnosis, while the ‘Lower Dementia Risk’ (LR) group had
none.
Age, gender and MAPT-genotype matched controls, with no history
of neurological disease, self-reported memory problems or depression
were recruited via the Cambridge Bioresource (http://www.
cambridgebioresource.org.uk).
Exclusion criteria for all participants consisted of the presence of-:
another neurodegenerative, chronic inflammatory or autoimmune dis-
order, current clinically significant infection, surgery within last month,
vaccinations in the last 3 weeks, use of steroids (within last 3 months),
aspirin>75 mg or ibuprofen/nonsteroidal anti-inflammatory drugs
(within 2 weeks) or long-term immunosuppressant drugs (within 1 year).
2.2. Clinical data acquisition and sample collection
Participants attended for three visits at monthly intervals. Data
gathered included demographic data, medical and drug history and
comorbidity status (Cumulative Illness Rating Scale (CIRS) (Parmelee
et al., 1995)). Verbal screening for inter-current infections was per-
formed to avoid sampling during periods of illness. Clinical assessments
included the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS), HY scale, Addenbrooke’s Cognitive Ex-
amination-Revised (ACE-R), semantic fluency (animals in 90s) and
pentagon copying.
Venous blood (up to 50 ml) was sampled at each visit and used for
serum extraction and/or Peripheral Blood Mononuclear Cell (PBMC)
isolation and subsequent ex-vivo immunocytochemistry/flow cyto-
metry or CD14+ cell separation. All samples were collected between
9.00 and 11.00am, with no imposed medication changes. PD/control
samples paired by age, gender and genotype were processed in parallel
on the same day.
2.3. Sample processing
2.3.1. PBMC isolation, immunocytochemistry and flow cytometry
PBMCs were extracted using the standard Ficoll gradient method
and subjected to immunocytochemistry and flow cytometry as pre-
viously described (Appendix A) (Wijeyekoon et al., 2018), to measure
key monocyte cell surface markers.
The antibody panel used for flow cytometry consisted of CD14 –
APC-H7, CD16 – PerCP-Cy5.5, HLA-DR – BV605, TREM2 – APC, TLR2 –
PE, TLR4 – BV421 (Table A.1). Monocytes were gated and analysed as
described in the literature (Ziegler-Heitbrock and Hofer, 2013)
(Fig. 1A) and as detailed in Appendix A.
2.3.2. Serum sample processing and assays
Blood samples for serum collection were left to clot for 15 min and
centrifuged at 2000 rpm for 15 min at room temperature. The separated
serum was stored in 200–400 µl aliquots, frozen at −80 °C and thawed
before use. The following assays were performed (see Appendix A for
further details).
2.3.2.1. Mesoscale Discovery (MSD) platform electrochemiluminescence
assays. Samples from each of the 3 visits were processed in duplicate
according to the manufacturer’s instructions for the MSD V-Plex 10-spot
Pro-inflammatory panel 1 assay (Interferon (IFN)-γ, IL-1β, IL-2, IL-4, IL-
6, IL-8, IL-10, IL-12p70, IL-13 and TNFα; 1:2 dilution; 50ul per well);
MSD V-Plex Human C-Reactive Protein (CRP) assay (1:1000 dilution;
25ul per well); MSD Human Alpha-Synuclein Assay (1:10 dilution; 25ul
per well).
Readings were obtained using the MSD SECTOR Imager. Data was
exported and analysed using the MSD Discovery Workbench software.
Fig. 1. Monocyte subtypes. (A) – Flow cytometry gating strategy for monocytes and monocyte subtypes Singlets are identified by plotting Forward Scatter-Area (FSC-
A) versus Forward Scatter-Width (FSC-W) and excluding cells with multiples of a single width size. Monocytes are broadly distinguished using tight gates based on
FSC-A (size) and Side Scatter-Area (SSC-A) (granularity/internal complexity). Monocyte subtypes are distinguished based on CD14 and CD16 expression –Classical
(CD14 high, CD16 negative); Intermediate (CD14 high, CD16 positive); Non-Classical (CD14 low, CD16 high). (B) – Total monocytes (as a percentage of PBMCs) in all
patients and controls; overall and within dementia risk groups (Parkinson’s disease = red triangles; Controls = yellow circles). (C),(D),(E)-Monocyte Subtypes. (C)
Classical, (D) Intermediate and (E) Non-Classical monocytes (as percentage of total monocytes) in Parkinson’s disease patients and controls; overall and within
dementia risk groups (Parkinson’s disease = red; Controls = yellow). **Significance withstood Bonferroni correction for multiple testing within the relevant
category. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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2.3.2.2. Additional assays-: Caspase-1, soluble CD14, soluble TREM2 and
bacterial endotoxin. Additional markers were measured from remaining
serum aliquots and included-: caspase-1 (Wang et al., 2016; Codolo
et al., 2013); bacterial endotoxin (a primary ligand for TLR4) and
soluble CD14, as markers of microbial translocation (Morris et al.,
2015; Kelesidis et al., 2012); and soluble TREM2, as an indicator of
TREM2 shedding (Feuerbach et al., 2017).
Samples were analysed in duplicate using ELISA assays for caspase-
1(R and D Systems) (2:3 dilution), soluble TREM2(Cloud-Clone Corp.)
(1:2 dilution), and soluble CD14(R and D systems) (1:800 dilution),
following the manufacturer’s instructions (Appendix A).
Serum endotoxin was measured using the Pierce Limulus Amoebocyte
Lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Thermo Scientific)
(40 samples) and the LAL Chromogenic Endpoint Assay (Hycult Biotech)
(36 samples), due to supplier shortages of the former during the course of
the study. Samples from PD and control pairs were analysed using the
same plate and kit. The results from both batches covered similar ranges
(Thermo Scientific kit – 0.46 – 6.32 EU/ml; Hycult Biotech kit – 0.46 –
5.00 EU/ml). All samples were assayed in duplicate according to the
manufacturer’s instructions, with 1:50 dilution.
2.3.3. Monocyte separation
Monocytes were separated using MACS® CD14 magnetic beads
(Miltenyi Biotec) as per the manufacturer’s instructions and as pre-
viously detailed (Appendix A) (Wijeyekoon et al., 2018).
2.3.4. Fluorescent alpha-synuclein endocytosis assays
Monocyte uptake of recombinant human alpha-synuclein (1–140)
HiLyteTM Fluor 488 (Anaspec) was assessed in standard medium (clear
Roswell Park Memorial Institute (RPMI) culture medium and 10%
Foetal Calf Serum (FCS)), and in autologous serum (Appendix A).
Titration and time course experiments were performed prior to study
commencement, to optimise concentrations and end time points. Final
assays were run using 10,000 ng/ml of alpha-synuclein for an incuba-
tion period of 90 min. Alpha-synuclein uptake was assessed and
quantified using flow cytometry. Representative post-uptake monocyte
samples were used for imaging using fluorescence microscopy.
2.3.5. Monocyte alpha-synuclein and caspase-1 secretion assays
Separated monocytes were cultured in RPMI and 10% FCS under
standard conditions at a concentration of 1x106 cells per ml per well,
with and without LPS (1 ng/ml). Paired PD and control cultures, with
and without LPS, were performed in parallel. The supernatant was
collected at 24 h, aliquoted and stored at −80 °C.
Supernatants were analysed for alpha-synuclein and caspase-1 ac-
cording to the manufacturer’s instructions as detailed above and in
Appendix A. Supernatants were diluted 1:10 for alpha-synuclein and 2:3
for caspase-1 in the appropriate buffers and were assayed in duplicate.
2.3.6. Monocyte lysates
Monocytes were lysed in homogenisation solution (Appendix A),
and their total protein concentration was measured using a
Bicinchoninic acid (BCA) assay (Appendix A). Alpha-synuclein and
caspase-1 levels were measured in monocyte lysates using the assays
and dilutions described above. Western blots for alpha-synuclein and
caspase-1 were performed on the monocyte lysates, with β-actin as
loading control (Appendix A).
2.4. Statistical analysis
Data was analysed using IBM SPSS version 25 or GraphPad Prism 7.
Experimental outliers> 3 standard deviations (SD) above or below the
mean were excluded and normality was assessed using the Shapiro-Wilk
test prior to analysis. Due to the paired experimental methodology,
group comparisons were performed for PD cases overall and within
each a priori determined risk group versus paired controls using paired
two-tailed t-tests (parametric) or Wilcoxon matched-pairs tests (non-
parametric) as appropriate. Bonferroni correction for multiple testing
was used across each assay category (e.g. monocyte subtypes, monocyte
surface expression markers, all serum assays). All monocyte markers
and serum markers with a PD-Control uncorrected significant difference
of p < 0.05 were included in a Principal Components Analysis (PCA).
Relationships between monocyte/serum markers and clinical vari-
ables (MDS-UPDRS motor, ACE-R and semantic fluency scores) were
assessed using bivariate correlation analysis. Markers reaching sig-
nificance (p < 0.05) were included in multiple regression analyses for
each clinical variable with appropriate confounders. Correlations be-
tween PCA component scores and clinical variables were compared
using similar methods.
2.5. Plasma markers and disease progression
Stored baseline plasma samples were available for another cohort of
93 patients (Incidence of Cognitive Impairment in Cohorts with
Longitudinal Evaluation in Parkinson's Disease (ICICLE‐PD) Cambridge
cohort) who were newly diagnosed with PD and recruited between
2009 and 2011 from community/outpatient clinics in Cambridge,
United Kingdom. Details of recruitment, assessment and follow up of
the patients have been previously published (Yarnall et al., 2014).
Subjects were assessed clinically as previously described (Williams-
Gray et al., 2016), at baseline, 18 and 36 months.
Venous blood samples (EDTA tubes) were obtained at baseline entry
to the study and plasma extracted by centrifugation (2000 rpm for
15 min), with storage at −80 °C. On use, plasma was thawed and pro-
cessed for alpha-synuclein and caspase-1(1:50 dilution) (Appendix A).
Relationships between baseline plasma markers and longitudinal
clinical progression were analysed using simple bivariate correlation
analyses. Significant correlations were further examined using multiple
regression analyses with relevant confounders.
2.6. Data availability
Data related to the findings of this study will be available from the
corresponding author, upon reasonable request.
Table 1
Demographic details of participant groups (Mean ± Standard Deviation). *p < 0.05. MDS-UPDRS – Movement Disorder Society Unified Parkinson’s Disease Rating
Scale; ACE-R – Addenbrooke’s Cognitive Examination- Revised; CIRS – Cumulative Illness Rating Scale.
Variable Higher Risk (HR) Group Lower Risk (LR) Group HR vs LR Parkinson’s disease (p)
Parkinson’s disease Paired Controls p Parkinson’s disease Paired Controls p
Number (n) 23 23 18 18
Age (years) 70.13 ± 5.96 69.43 ± 5.40 0.680 66.33 ± 6.36 66.39 ± 5.71 0.978 0.056
Gender (% male) 73.9 73.9 0.631 61.1 61.1 0.633 0.295
Disease Duration (years) 4.26 ± 1.09 4.26 ± 1.23 0.994
MDS-UPDRS motor score 38.35 ± 12.71 31.00 ± 10.78 0.062
Equivalent Levodopa dose 493.34 ± 269.78 717.03 ± 279.27 0.013*
ACE-R score 89.96 ± 9.94 96.88 ± 2.31 0.008*
CIRS Total Score 4.30 ± 2.05 5.39 ± 2.99 0.177
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Fig. 2. Monocyte surface markers. Total monocyte marker expression in Parkinson’s disease cases versus paired controls; overall and within risk groups. Graphs
showing total monocyte MFI (Median Fluorescence Intensity) ratios (Test/Isotype) ((A), (C), (E), (G)) and percentage monocytes positive ((B), (D), (F), (H)).
(Parkinson’s disease = red triangles; Controls = yellow circles). **Significance withstood Bonferroni correction for multiple testing within the relevant category.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




41 Parkinson’s disease cases and 41 paired matched controls were
recruited (23 pairs HR group and 18 pairs LR group) (Table 1).
3.2. Monocyte markers
There were no significant differences in total monocytes (as a per-
centage of PBMCs) between PD and paired controls, overall (t
(40) = 0.5446, p = 0.5891) nor in both risk groups (Fig. 1B). PD cases
had a statistically significant (withstanding Bonferroni correction for
multiple testing) higher proportion of classical monocytes (W =−445,
p = 0.0014), with trends (uncorrected significance) towards corre-
spondingly lower intermediate (t(37) = 2.334, p = 0.0251) and non-
classical (W = 278, p = 0.0433) monocytes, compared to paired
controls (Fig. 1C-E). Risk group analysis revealed a trend towards
higher classical monocyte percentages in the HR PD group (W=−141,
p = 0.0127) compared to paired controls, but not the LR group
(Fig. 1C).
TLR4+ monocytes constituted a higher percentage in PD compared
to controls (W = −204, p = 0.0128), with statistical significance in
the HR PD group (W =−124, p = 0.0004). The percentage of TLR2+
monocytes was also significantly higher in all PD cases (W = −347,
p = 0.0078) compared to controls and within the HR PD group
(W = −134, p = 0.0107) (Fig. 2A-D).
Monocyte TREM2 and HLA-DR measures did not differ between PD
cases and controls. However, HR group PD cases had significantly
higher monocyte TREM2 expression (t(19) = 2.977, p = 0.0077)
compared to paired controls and a trend towards a higher percentage of
TREM2+ monocytes (t(20) = 2.216, p = 0.0385), while LR PD cases
demonstrated a trend towards a lower percentage of TREM2+ mono-
cytes (t(17) = 2.457, p = 0.0250) (Fig. 2E-H).
Additional analyses performed on the Classical monocyte sub-po-
pulation indicated similar patterns of changes to Total monocytes in all
measured markers, but with decreased significance overall, possibly
due to smaller cell numbers within the subpopulation (Appendix A, Fig.
A.5).
3.3. Monocyte markers and clinical variables
Monocyte HLA-DR surface expression levels correlated with better
cognitive function (higher ACE-R (r = 0.402, p = 0.015) and semantic
fluency (r = 0.440, p = 0.006)) and motor function (lower UPDRS
motor score (r = −0.398, p = 0.016)). There were no correlations
with levodopa equivalent dose, suggesting the associations were un-
likely to be medication driven (Fig. 3). There were no significant cor-
relations between clinical scores and other monocyte marker measures
(data not shown).
Multivariate regression analysis with the UPDRS motor score, se-
mantic fluency or ACE-R scores as the dependent variables, and age,
disease duration, levodopa equivalent dose and CIRS comorbidity score
as potential confounders, confirmed the relationships with total
monocyte HLA-DR surface expression level (Table A.2).
3.4. Serum markers
Serum alpha-synuclein concentration was significantly lower in PD
cases compared to controls, regardless of risk group (Overall W = 810,
p < 0.0001; HR W = 276, p < 0.0001; LR W = 147, p < 0.0001)
(Fig. 4A).
Fig. 3. Monocyte HLA-DR expression and clinical data. Relationships between Total Monocyte HLA-DR expression (Test/Isotype MFI Ratio) and clinical data – (A)
Semantic Fluency. (B) MDS-UPDRS III motor score. (C) ACE-R score. (D) Absence of correlation with Levodopa equivalent dose.
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Serum caspase-1 was also significantly lower in PD compared to
controls, regardless of risk group (Overall W = 596, p < 0.0001; HR
W = 139, p = 0.0013; LR W = 161, p < 0.0001) (Fig. 4B).
Serum endotoxin was higher in PD compared to controls
(W=−287, p = 0.0231), with a non-significant trend in the HR group
(W = −79, p = 0.0898) (Fig. 4C).
Fig. 4. Serum markers and Principal Components Analysis. (A)-(E) – Concentrations of serum (A) alpha-synuclein, (B) caspase-1, (C) endotoxin, (D) soluble CD14 and
(E) soluble TREM2 in Parkinson’s disease patients and controls and within Parkinson’s dementia risk groups. (Patients = red triangles; Controls = yellow circles).
**Significance withstood Bonferroni correction for multiple testing within the relevant category.(F)-(H) – Summary of Principal Components Analysis (PCA)
component score comparisons between all Parkinson’s patients and paired controls and within risk groups. (Patients = red triangles; Controls = yellow
circles).Component 1 – (+)serum alpha-synuclein, (+)caspase-1 and (−)TLR2+ monocytes; Component 2 – (+)serum endotoxin, (+)monocyte TREM2 and (−)
serum alpha-synuclein; Component 3 – (+)classical monocyte percentage and (−)serum alpha-synuclein. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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Serum IL-2 and IFN-γ displayed trends towards decrease in the HR-
PD group, but there were no statistically significant case-control dif-
ferences in the serum concentrations of measured cytokines, CRP, so-
luble CD14 or soluble TREM2 in patients compared to controls (Tables
A.3 and A.4; Fig. 4D,E).
For both monocyte markers and serum variables, gender-stratified
paired comparisons indicated overall similar trends in all markers
within both genders, though significance was greater in the male group,
which may relate to the larger sample size (> 68% male) (data not
shown).
3.5. Serum markers and clinical variables
MDS-UPDRS motor scores correlated negatively with serum alpha-
synuclein (r = −0.407; p = 0.010) (Fig. A.8, but this did not remain
significant in a multiple regression analysis with age, disease duration,
Levodopa equivalent dose and CIRS total score as potential confounders
(Table A.5).
3.6. Principal component analysis (PCA)
In order to explore relationships between key markers, a PCA was
performed, using all participant data on all monocyte markers, and
serum markers with uncorrected significant results on overall PD-
Control paired analysis (Appendix A).
A three-component solution cumulatively explained 67.64% of the
total variance. The principal component loadings of the rotated solution
are shown in Table 2. Component 1 (32.48%) was mainly driven by (+)
serum alpha-synuclein, (+)caspase-1 and (−)TLR2+ monocytes.
Component 2 (19.48%) was mainly driven by (+)serum endotoxin, (+)
monocyte TREM2 and (−)serum alpha-synuclein. Component 3
(15.67%) was mainly driven by (+)classical monocyte percentage and
(−)serum alpha-synuclein.
Paired comparisons of PCA components between PD and controls
and within the risk groups (Fig. 4F,(G),(H)), indicated that Component
1 was significantly lower in all PD versus controls (W = 397,
p < 0.0001) and in both HR (W= 78, p = 0.0256) and LR (W = 118,
p = 0.0001) groups, while Component 2 was significantly higher in all
PD versus controls (W = −299, p = 0.0015) and within the HR group
(W = −112, p = 0.0004). Component 3 was also significantly higher
in all PD versus controls (W = −297, p = 0.0016), with elevation
within the LR (W = −84, p = 0.0151) and the HR (W = −70,
p = 0.0479) groups. Bivariate correlation analyses did not show any
associations between PCA components and measured clinical variables.
Key relationships identified through PCA were further explored,
including the relationship between endotoxin and TREM2 (component
2) and between alpha-synuclein and caspase-1 (component 1).
3.7. Endotoxin and TREM2
Serum endotoxin did not directly correlate with monocyte surface
TREM2. However, it demonstrated a significant, but weak positive
correlation with soluble TREM2 (r = 0.1613, p = 0.0005), which re-
mained significant on multivariate linear regression analysis, with
monocyte TREM2 and age as potential confounders (Fig. A.9; Table
A.6).
3.8. Alpha-synuclein and Caspase-1
In addition to clustering within the PCA (component 1), serum
alpha-synuclein and caspase-1 were significantly positively correlated
with each other (r = 0.382, p = 0.001) (Fig. 5I). In order to further
investigate potential mechanistic factors relating to the serum changes
seen in these proteins (e.g. differences in cellular uptake and release),
additional functional assays and analyses were performed using ex-vivo
monocytes from subsets of participants from the cohort.
3.8.1. Monocyte fluorescent alpha-synuclein uptake
Monocyte uptake of fluorescent monomeric alpha-synuclein was
assessed using standard medium, as well as an autologous serum en-
vironment (Fig. 5A-D). Autologous serum was used to better represent
the in-vivo intravascular environment (Wijeyekoon et al., 2018), while
the standard medium was used to study the intrinsic uptake ability of
the monocytes independent of serum factors.
There were no significant differences in fluorescent alpha-synuclein
uptake in standard medium between patients and controls (% positive
monocytes t(35) = 0.7691, p = 0.4470) (Fig. 5C,D). In autologous
serum, uptake was decreased across all groups, compared to standard
medium (t(50) = 46.45, p < 0.0001), but no significant case-control
differences were seen (t(27) = 1.685, p = 0.1034).
3.8.2. Monocyte alpha-synuclein and caspase-1 secretion
Monocyte secretion of alpha-synuclein and caspase-1 were not sig-
nificantly different between all PD and controls (Fig. 5E-H). However
alpha-synuclein secretion was decreased in HR cases compared to
paired controls, with (t(12) = 2.324, p = 0.0385) and without LPS
stimulation (t(13) = 2.555, p = 0.0240) (Fig. 5E,G). The number of LR
group pairs were insufficient for analysis.
Additionally, LPS led to increased secretion of caspase-1 overall,
with no relative difference in PD versus controls (Fig. 5F,H). However,
alpha-synuclein secretion did not increase with LPS stimulation
(Fig. 5E,G).
3.8.3. Monocyte lysate alpha-synuclein and caspase-1
Western blot analysis indicated the presence of higher molecular
weight alpha-synuclein and of caspase-1 in monocyte lysates in both PD
and controls (Fig. A.10A,B). Measurement of total alpha-synuclein and
caspase-1 levels in monocyte lysates (relative to total protein) using
MSD and ELISA assays, found no significant case-control differences
(Fig. A.10C,D).
However, similar to the serum findings, monocyte lysate alpha-sy-
nuclein and caspase-1 were also positively correlated with each other
(r = 0.603, p = 0.001) (Fig. 5J).
3.9. Alpha-synuclein and caspase-1 in a separate, larger incident PD cohort
Alpha-synuclein and caspase-1 were measured in baseline plasma
samples from the ICICLE-Cambridge cohort (n = 93; mean (standard
Table 2
Principal component loadings for the rotated solution of the PCA. Coefficients < 0.3 were suppressed and are shown in brackets. Coefficients> 0.3 are highlighted
in bold.
Variable Component 1 Component 2 Component 3 Communalities
Total Monocyte TLR2+ percentage −0.880 (−0.093) (−0.042) 0.785
Serum Caspase-1 0.801 (−0.275) (−0.093) 0.726
Serum Endotoxin (−0.120) 0.759 (0.056) 0.594
Total Monocyte TREM2 MFI ratio (0.058) 0.673 (−0.244) 0.515
Serum Alpha-synuclein 0.401 −0.536 −0.330 0.558
Classical Monocyte percentage (−0.012) (−0.072) 0.936 0.881
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deviation)-: age = 66.73 (6.92); disease duration = 0.81 (0.57); 60.2%
male).
The two proteins again demonstrated a significant positive corre-
lation with each other (Pearson’s r = 0.480, p < 0.001; Fig. 5K), re-
plicating findings in the primary study cohort. There were no sig-
nificant correlations between the baseline levels of either marker and
baseline or longitudinal cognitive/motor measures over 36 months
(data not shown).
4. Discussion
This study evaluated key peripheral innate immune markers linked
to PD, in a cohort of dementia risk stratified patients and carefully
matched controls. The findings confirmed that there are significant
peripheral innate immune changes in PD, with increased classical
monocytes and TLR positive monocytes, and further demonstrated that
these changes are most marked in those individuals at increased early
dementia risk. Monocyte TREM2 expression was also elevated in the
higher dementia risk group, while higher monocyte HLA-DR expression
correlated with better existing motor and cognitive performance.
The study has also uniquely shown that innate immune changes in
PD are accompanied by elevated serum levels of bacterial endotoxin,
suggesting that this may be playing a critical role in driving the innate
immune response and associated pathology. In addition, serum alpha-
synuclein was significantly decreased in PD, irrespective of dementia
risk group and had a close relationship with serum caspase-1-a key
component of the inflammasome pathway.
PCA confirmed the clustering of markers with similar patient-con-
trol group variations. In particular, component 1 was mainly driven by
alpha-synuclein and caspase-1 plus monocyte TLR2 and demonstrated
significant PD-control differences overall and in both risk groups.
Component 2 was driven by serum endotoxin, monocyte TREM2 and
serum alpha-synuclein, with significant overall PD-control differences,
predominant within the HR group. Component 3 was driven by the
classical monocyte percentage and serum alpha-synuclein, with sig-
nificant PD-control differences also overall and within both groups.
4.1. Monocyte changes in PD
The increase in classical monocytes (with corresponding decrease in
non-classical monocytes), and monocyte TLR2+ and TLR4+ mono-
cytes observed in this PD cohort confirms previous findings (Grozdanov
et al., 2014; Drouin-Ouellet et al., 2015). However, this study further
demonstrates that these changes are mainly driven by those at in-
creased risk of dementia.
Classical monocytes (up to 85% of total monocytes) are mainly in-
volved in phagocytosis, antigen presentation to adaptive immune cells
and cytokine secretion in response to TLR stimulation (Wong et al.,
2012; Mukherjee et al., 2015), although exact subtype functions may
vary under different clinical conditions (Lee et al., 2017b; Boyette et al.,
2017). Intermediate and non-classical monocytes may also be more
senescent cells, that increase with age (Ziegler-Heitbrock and Hofer,
2013) and derive from further differentiation of classical monocytes in
the bone marrow (Ong et al., 2018; Patel et al., 2017). At a systemic
level, LPS stimulation leads to depletion of monocyte numbers and on
recovery, classical monocytes appear to rise first (Tak et al., 2017).
Thus, the increased classical monocytes seen in PD compared to con-
trols, most prominent in the HR group, may reflect chronic exposure to
the increased endotoxin, in these patients. The data is also consistent
with our previous finding of reduced senescence markers in T lym-
phocytes in PD cases in this cohort (Williams-Gray et al., 2018).
The TLR2+ monocyte percentage varied inversely to alpha-synu-
clein and caspase-1 in PCA component 1. TLR2 is an innate immune
receptor to DAMPs/PAMPs (e.g. bacterial-derived lipids, amyloids) and
endogenous ligands including forms of alpha-synuclein (Bryant et al.,
2015; Kim et al., 2013,2016a; Codolo et al., 2013), and can also facil-
itate activation of the inflammasome pathway (Rapsinski et al., 2015)
and caspase-1.
TLR4 has a major role in the transduction of the cellular response to
bacterial endotoxin and its stimulation leads to activation of Nuclear
factor-kappa B (NF-κB) and transcription of cytokine precursors (e.g. IL-
6, IL-1β) and inflammasome components (Lu et al., 2008), potentially
leading to a relative ‘priming’ effect on inflammasome activation in
patients.
Thus, the TLR2 and TLR4 monocyte changes seen may reflect in-
creased potential to respond to DAMPS/PAMPS including alpha-synu-
clein, with subsequent promotion of caspase-1 activation, intracellular
accumulation/aggregation and inflammation, mainly in the HR pa-
tients.
Significant elevation of monocyte TREM2 was also observed in the
HR patient group. TREM2 is involved in bacterial clearance during
sepsis (Chen et al., 2013) and may have a role in regulating TLR
pathway signalling (Hamerman et al., 2006; Kober and Brett, 2017).
Increased monocyte TREM2 expression is seen in Alzheimer’s disease
(Hu et al., 2014) and TREM2 can act as a microglial receptor for
amyloid-beta, with involvement in phagocytosis and clearance of Alz-
heimer’s pathology (Zhao et al., 2018; Lee et al., 2018). Interestingly,
this may suggest that TREM2 may be raised in response to chronic TLR
stimulation and indicates possible immunological similarities between
high dementia risk PD and Alzheimer’s disease.
Monocyte HLA-DR expression did not differ between PD cases and
controls, but did significantly correlate with clinical variables in disease
(lower levels associated with worse cognitive/motor function). Low
monocyte HLA-DR is a key feature of monocyte tolerance, typically
known to occur subsequent to stimuli such as LPS/endotoxin or sepsis,
and is associated with decreased antigen presentation, cytokine pro-
duction and changes in phagocytosis, and mediated by epigenetic and
metabolic factors (Pfortmueller et al., 2017; Saeed et al., 2014; Cheng
et al., 2014). These immune disruptions associated with low HLA-DR
may contribute to impaired clearance of pathological proteins, neu-
ronal dysfunction and subsequent cognitive and motor impairment. In
contrast, PD animal models involving acute toxin/protein injections/
pathology suggest deleterious effects of increased HLA-DR (Williams
et al., 2018; Harms et al., 2013). This may indicate that in the acute
situation seen in animal models, the detrimental effects of HLA-DR
(e.g.pro-inflammatory cytokine release) outweigh the beneficial effects
of increased antigen presentation/clearance, whereas in the chronic
clinical situation, the beneficial effects of increased HLA-DR mediated
pathology clearance outweigh the detrimental effects. However, more
detailed prospective studies will be required to further investigate these
effects and hypotheses.
The PD-control marker changes seen in total monocytes may mainly
Fig. 5. Alpha-synuclein and Caspase-1. (A), (B) – Fluorescence microscope images of monocytes which have taken up fluorescent alpha-synuclein- HiLyteTM Fluor
488 at 90 min. Hoechst staining identifies cell nuclei. (a) 20X; (b) 40X. (C), (D) – Monocyte fluorescent alpha-synuclein uptake in standard medium and in autologous
serum – (C) percentage alpha-synuclein positive monocytes; (D) total monocyte MFI ratio. (Medium- Patients = 35, Controls = 35; Serum- Patients = 27,
Controls = 28) (Patients = red triangles; Controls = yellow circles). (E),(F),(G),(H) – Alpha-synuclein and caspase-1 in monocyte 24 h culture supernatants without
(E, F) and with (G, H) LPS, in all participants and within risk groups. (Patients = red triangles, Controls = yellow circles). (All participants- Patients = 18,
Controls = 20; Higher Risk Patients = 15, Controls = 16; Lower Risk Patients = 3, Controls = 4). (I), (J) Graphs showing significant relationship between alpha-
synuclein and caspase-1 in serum (I) and monocyte lysates (J). (K) ICICLE-Cambridge cohort – Relationship between alpha-synuclein and caspase-1 in plasma samples
collected at study baseline. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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reflect changes seen in the pre-dominant classical monocyte subtype.
However, analysis of the more limited data from Intermediate and Non-
Classical monocytes also indicated broadly similar trends in these
subtypes overall (Appendix A). Further detailed studies specifically
investigating monocyte subtype and related innate immune cell (e.g.
dendritic cell) changes in PD will be important in future work.
4.2. Serum endotoxin
To our knowledge, this is the first study to directly demonstrate
elevated serum endotoxin in PD, particularly in patients with increased
risk for early dementia. Endotoxin is a principal component of the outer
membrane of gram-negative bacteria and its major source in serum is
translocation of gram-negative bacterial components across gastro-
intestinal/other mucosal membranes (Bischoff et al., 2014; Kelesidis
et al., 2012; Alexopoulou et al., 2017) and thus the findings indicate
greater bacterial translocation in PD, particularly in the HR group.
Accordingly, previous studies have demonstrated greater gastro-
intestinal permeability in PD patients, with lower levels of LPS binding
protein (LBP) (indicating less LPS neutralisation) and increased gut
staining for Escherichia Coli bacteria (Forsyth et al., 2011; Perez-Pardo
et al., 2019). One smaller study (Hasegawa et al., 2015) found no dif-
ference in serum endotoxin, but lower LBP (Pal et al., 2015;
Vreugdenhil et al., 2003) in PD patients, suggesting an LPS-LBP im-
balance with increased LPS activity. Intestinal microbiome differences
are also seen in PD (Scheperjans et al., 2015) and may modulate disease
pathology and manifestation (Sampson et al., 2016; Dodiya et al.,
2018).
Low level chronic elevation of serum endotoxin in PD may be an
important mediator of innate immune changes. At a cellular level, en-
dotoxin/LPS acts via TLR4, activating NF-κB and transcription of pro-
inflammatory cytokines and proteins including pro-IL-1β and NLRP3
(Lu et al., 2008). Intracellular LPS can also activate the non-canonical
NLRP3 inflammasome pathway via caspase-11 (caspase-4 or -5 in hu-
mans), leading to caspase-1 activation (Man and Kanneganti, 2015;
Stowe et al., 2015). Thus, endotoxin would stimulate both TLR and
inflammasome pathways, potentially resulting in cumulative patho-
genic effects.
Endotoxin also has direct effects on alpha-synuclein, stimulating
increased production in macrophages (Tanji et al., 2002) and specific
fibril formation (Kim et al., 2016b; Bhattacharyya et al., 2019). Fur-
thermore, in-vivo studies have demonstrated synergistic deleterious
effects of LPS and alpha-synuclein on PD related pathology and neu-
ronal survival (Gao et al., 2011a; Zhang et al., 2018). Amyloid beta and
tau pathology, which are additionally related to cognitive impairment,
have also been linked to endotoxin-associated inflammation (Asti and
Gioglio, 2014; Kitazawa et al., 2005), with LPS stimulation leading to
increased tau production (Bhaskar et al., 2010; Gardner et al., 2016).
Peripheral endotoxin may also lead to neuroinflammation in the
brain, as measured using PET imaging of microglial activation in
human subjects following peripheral intravenous injection of low dose
LPS (Sandiego et al., 2015). It is unclear whether the microglial acti-
vation is a direct consequence of endotoxin in CNS tissues, or of sec-
ondary immune cell/protein CNS entry. However, post-mortem studies
have found LPS/microbial proteins in relation to amyloid-beta plaques
in Alzheimer’s disease brains, indicating the presence of endotoxin itself
within the brain (Zhan et al., 2016).
As discussed above, variable extent and duration of serum en-
dotoxin exposure (Morris et al., 2015) may also subsequently influence
disease pathology through monocyte tolerance and effects on HLA-DR/
protein clearance functions (Mukherjee et al., 2015; Kobayashi et al.,
2016; de Lima et al., 2014), in addition to driving an innate immune
response and promoting aggregation, particularly in the HR group.
PCA Component 2 indicated a possible relationship between en-
dotoxin and monocyte TREM2. As discussed above, TREM2 is involved
in bacterial clearance (Chen et al., 2013) and may be raised in response
to elevated endotoxin and TLR signalling in PD (Hamerman et al., 2006;
Kober and Brett, 2017). Opposite to this elevation seen in HR PD,
monocyte TREM2 is decreased in LR PD relative to controls, consistent
with the lack of rise in endotoxin/TLR in LR PD. Furthermore, serum
endotoxin was positively correlated with sTREM2, which would be
consistent with the sTREM2 rise seen with infection related immune
activation (Gisslén et al., 2019).
4.3. Alpha-synuclein and Caspase-1
Serum alpha-synuclein and caspase-1 (major factors in PCA com-
ponent 1), were significantly lower in PD compared to controls re-
gardless of risk group. The study has also discovered a positive re-
lationship between these proteins in serum, plasma and monocyte
lysates. This would be consistent with co-accumulation/aggregation
and/or parallel changes in production and breakdown.
Alpha-synuclein is physiologically produced, released and taken up
by many cells, including peripheral blood cells (Shin et al., 2000;
Barbour et al., 2008; Tyson et al., 2016) and decreased levels are seen in
PD blood (Gupta et al., 2015; Li et al., 2007; Ishii et al., 2015) and
cerebrospinal fluid (CSF) (Eusebi et al., 2017). This may suggest alpha-
synuclein is being sequestered out of bio-fluids by aggregation and/or
intracellular accumulation. Higher patient plasma alpha-synuclein
found in some studies (Lin et al., 2017; Duran et al., 2010), may relate
to red cell/platelet leakage during centrifugation (Shi et al., 2010).
The decreased monocyte alpha-synuclein release seen in the HR
patient group may be an additional contributor to lower serum alpha-
synuclein in this group and could relate to exocytosis dysfunction in PD
(Lautenschläger et al., 2017; Logan et al., 2017). Further, increased
aggregated alpha-synuclein species found in PD (Parnetti et al., 2019)
may also cause confounding issues with detection by the immunoassays
used.
Caspase-1, a key component of the inflammasome pathway (Strowig
et al., 2012), is produced by many cell types, including monocytes
(Shamaa et al., 2015). Activation of inflammasome complexes (e.g.
Nucleotide-binding domain, leucine rich repeat containing receptor
family pyrin domain containing-3 (NLRP3)) (Strowig et al., 2012; Man
and Kanneganti, 2015), triggered by a variety of stimuli related to
homeostatic disruption (e.g. microbial/viral RNA/DNA components,
ATP, uric acid) (Man and Kanneganti, 2015), leads to activation of
caspase-1, which subsequently cleaves other proteins (e.g. pro-IL-1β,
pro-IL-18), leading to inflammation.
Activated caspase-1 can also cleave alpha-synuclein, making it more
aggregable (Wang et al., 2016) and our observation of decreased serum
caspase-1 and its correlation with alpha-synuclein may suggest they are
both being sequestered out of serum, possibly into cells or aggregates,
as a common process in PD. Studies, including our own work (White
et al., 2018), have also shown that alpha-synuclein can activate in-
flammasome pathways causing inflammatory cytokine production
(Codolo et al., 2013; Zhou et al., 2016). Hence both alpha-synuclein
and caspase-1 may interact in a bidirectional loop, which contributes to
both increased inflammation and intracellular alpha-synuclein ag-
gregation in PD.
In contrast to the current study, Zhou et al. found increased caspase-
1 in a smaller cohort of twelve patients compared to controls (Zhou
et al., 2016). However, differences in patient/control demographics and
longer delays prior to higher speed centrifugation (increasing leakage
risk of intracellular caspase-1) in that study, may have contributed to
the differences.
The alpha-synuclein and caspase-1 related monocyte assays may
additionally suggest functional impairment of monocytes in PD.
Previous studies have found TLR4-mediated stimulation of microglial
phagocytosis and alpha-synuclein uptake (Fellner et al., 2013; Venezia
et al., 2017) and increased caspase-1 release on endotoxin stimulation
of PBMCs (White et al., 2018). However, PD monocytes in this study
demonstrated no increased alpha-synuclein uptake or LPS-induced
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caspase-1 secretion, contrary to what might be expected given their
higher TLR4+ percentage, compared to controls.
4.4. Relevance of peripheral immune changes to PD pathology
Peripheral changes in alpha-synuclein and innate immune and mi-
crobial related molecules may provide relevant insights into PD pa-
thogenesis and heterogeneity. In particular, multiple routes of
communication between the CNS and periphery, (including lymphatic
routes (Louveau et al., 2015), blood/brain barrier, choroid plexus, CSF,
meninges and the peripheral/autonomic nervous system (Su and
Federoff, 2014)), indicate that peripheral changes could be influenced
by and/or influence CNS pathology. Importantly, peripheral LPS in-
jection in humans leads to rapid central microglial activation on PET
imaging and highlights the strength of influence of peripheral immune
factors on the CNS (Sandiego et al., 2015).
Fig. 6. Summary. Schematic diagram of key innate immune related markers, pathological pathways and hypothesised interactions relevant to clinical progression in
Parkinson’s disease, based on insights from this study and previous literature. The cellular section represents any cell in which the relevant markers/processes are
present. The outcomes of these processes, together with decreased clearance and circulatory spread, could ultimately contribute towards increased neuronal/synaptic
dysfunction, cortical pathology, and consequent cognitive/clinical progression. LPS – Lipopolysaccharide (Endotoxin); DAMPs/PAMPs – Damage/Pathogen
Associated Molecular Patterns; NF-κB – Nuclear Factor Kappa B; TREM2- Triggering Receptor Expressed on Myeloid cells-2; HLA-DR- Human Leukocyte Antigen-DR
subtype; TLR- Toll-Like Receptor; IL- Interleukin; TNF – Tumour Necrosis Factor.
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Alpha-synuclein pathology is present in the gut and periphery as
well as the brain in PD (Forsyth et al., 2011) and some of the peripheral
immune changes observed may be directly reflective of such pathology.
Also, peripheral factors such as the microbiome (e.g. gut) may have
parallel peripheral immune and CNS effects (Marizzoni et al., 2017),
including in PD (Scheperjans et al., 2015; Unger et al., 2016).
In addition to potential direct contributions towards the pathology,
peripheral monocytes constitute an easily repeatedly accessible source
of cells from a living patient and may provide insights into generic
cellular processes disrupted in PD. While monocytes are considered to
contribute towards choroid plexus macrophages (Kierdorf et al., 2019),
genetic variations in central microglia function have been paralleled in
related peripheral monocytes (Bradshaw et al., 2013), indicating that
monocytes could act as peripheral proxies or models for particular as-
pects of study of microglia and CNS innate immune cells in PD.
5. Limitations
Our sample size was limited by the feasibility of collecting patient-
control samples paired by age, gender and MAPT haplotype for parallel
processing of samples. Although this was advantageous in terms of
ensuring that each patient-control pair experienced minimal variations
due to methodological issues, it limited power which may explain our
inability to detect previously observed differences in inflammatory
cytokines (Williams-Gray et al., 2016; Qin et al., 2016). In addition,
despite practical corrections for multiple comparison testing, we cannot
exclude the possibility of Type I errors.
Dopamine may influence immune cell properties (Papa et al., 2017)
and Levodopa/dopaminergic medications could therefore cause po-
tential confounding effects. However, none of the measured markers
had any relationship with the Levodopa equivalent dose.
6. Conclusions
The observed changes in monocyte and serum markers indicate
significant innate immune involvement in early-moderate PD, with
differential and more marked effects in those with greater clinical im-
pairment and at increased risk for early cognitive decline, suggesting
that certain immune changes may be relevant to faster disease pro-
gression. Relevant mechanistic pathways and hypothesized interactions
are summarised in Fig. 6.
Higher endotoxin in those patients with higher dementia risk sug-
gests that greater microbial translocation may be an important factor in
driving pathology, whilst the association between low monocyte HLA-
DR and poor clinical status suggests that impaired antigen presentation
may also contribute to increased pathology and neurodegeneration.
Alpha-synuclein and caspase-1 appear to be closely associated and
may have reciprocal effects which contribute to inflammasome acti-
vation and intracellular alpha-synuclein aggregation in all PD.
The findings need to be replicated and the extent to which the
clinical differences are simply correlated with, or are a consequence of,
immune changes will require further prospective longitudinal studies.
Measurement of serum LBP and other microbial translocation markers
(e.g. bactericidal-permeability increasing protein (BPI) (Alexopoulou
et al., 2017)), epigenetic markers associated with monocyte endotoxin
tolerance and other inflammasome pathway components (e.g. NLRP3
and Apoptosis-associated Speck-like protein containing a C-terminal
caspase-recruitment domain (ASC) specks (Gordon et al., 2018;
Franklin et al., 2018)) would provide further insights into involvement
of these pathways in PD.
A clearer mechanistic understanding of how innate immune path-
ways contribute to disease progression and dementia may open up new
therapeutic avenues and enable targeted trials of specific immune/mi-
crobial related therapies (e.g. caspase-1/inflammasome inhibitors
(Bassil et al., 2016; Flores et al., 2018; Coll et al., 2015), TLR antago-
nists (Lucas and Maes, 2013; Peri and Piazza, 2012; Kouli et al., 2019),
and gut bacterial translocation reduction therapies (Fukui, 2017;
Gangarapu et al., 2015)) in particular subgroups. Improving constipa-
tion/gastrointestinal health, and prevention/early treatment of infec-
tions may also be of relevance. Specific markers may have additional
value as biomarkers to monitor target engagement of immune-directed
therapies. Further detailed investigation of the components and re-
lationships highlighted in this study will be essential for progression
towards such clinical and therapeutic applications.
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